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Abstract
Background: Mirogabalin, which is approved for the treatment of peripheral neuropathic pain in Japan, is a ligand
for the α2δ subunit of voltage-gated calcium channels. Both pregabalin and mirogabalin act as nonselective ligands
at the α2δ-1 and α2δ-2 subunits. Mirogabalin has a unique binding profile and long duration of action. Pregabalin
has been reported to produce intolerable adverse effects in some patients. This study investigated outcomes
associated with mirogabalin administration in patients with peripheral neuropathic pain who ceased treatment with
pregabalin.
Methods: We retrospectively assessed peripheral neuropathic pain using the neuropathic pain screening questionnaire
(NeP score) in 187 patients (58 men, 129 women) who were treated with mirogabalin. All patients had switched from
pregabalin to mirogabalin due to lack of efficacy or adverse events. Differences in the treatment course (i.e., numeric rating
scale (NRS) scores) were compared using one-way analysis of variance with Bonferroni post hoc tests.
Results: The mean age of the patients was 72.3 years (range, 30–94 years), and the mean duration of disease was 37months
(range, 3–252months). After treatment with mirogabalin for 1 week, NRS scores significantly decreased compared with
baseline and continued to decrease over time. After 8weeks, NRS scores improved by ≥ 30% from baseline in 113 patients
(69.3%). Twenty-four patients (12.8%) stopped mirogabalin treatment due to adverse events. Somnolence (26.7%), dizziness
(12.3%), edema (5.9%), and weight gain (0.5%) were noted as adverse events of mirogabalin.
Conclusions: The results of this investigation indicate that mirogabalin is safe and effective for reducing peripheral
neuropathic pain.
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Background
The International Association for the Study of Pain de-
fined neuropathic pain as “pain caused by a lesion or dis-
ease of the somatosensory nervous system” [1].
Neuropathic pain results in multiple symptoms, including
spontaneous neurological pain, allodynia, hyperalgesia,
and numbness, and results in decreases in quality of life
(QOL) [2]. In addition, neuropathic pain may become in-
tractable [2]. Chronic low back pain is known to be due to
neuropathic as well as nociceptive pain mechanisms [3, 4].
Patients with neuropathic pain show higher ratings for
pain intensity with more comorbidities, such as depression
panic/anxiety disorder, and sleep disorders than those
with nociceptive pain [4]. It is thus important to deter-
mine which factors contribute to neuropathic pain at an
early stage and start appropriate drug therapy [5].
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Unfortunately, current treatment methods are not always
satisfactory [5].
Pregabalin is a ligand for the α2δ subunit of voltage-
sensitive calcium channels and is recommended as the
first-line drug for neuropathic pain in guidelines
around the world [6]. It decreases the release of neu-
rotransmitters such as glutamate, noradrenalin, and
substance P, which leads to pain relief [7]. Pregabalin
has been used in patients with neuropathic pain and
shown to be a cost-effective treatment [8, 9] that has a
positive impact on QOL [10, 11]. It is generally well
tolerated [12], and most adverse events are mild to
moderate [13]. Pregabalin binds to the α2δ-1 and α2δ-
2 subunits of presynaptic, voltage-dependent calcium
channels, which are widely distributed throughout the
central and peripheral nervous systems [14]. The most
frequently reported side effects of pregabalin include
dizziness and somnolence, which are related to the
central nervous system (CNS) [14]. Therefore, the clin-
ical utility of pregabalin may be limited by CNS ad-
verse events [14].
Mirogabalin, which is a potent and specific ligand for
the α2δ subunit of voltage-gated calcium channels, is an
orally administered gabapentinoid developed for the
treatment of peripheral neuropathic pain in Japan [15,
16]. This agent has the distinguishing feature of persist-
ently binding to the α2δ-1 subunit, which plays an im-
portant role in neuropathic pain [16]. This new drug is
reportedly well tolerated and well absorbed following
oral administration and was first approved for peripheral
neuropathic pain in 2019.
Although there are many positive reports associated
with pregabalin, some patients have moderate adverse
events [14]. Tetsunaga et al. reported that somnolence
(46.9%), dizziness (18.8%), weight gain (9.4%), and rash
(4.7%) were noted as side effects of pregabalin [17]. No
reports regarding the treatment outcomes with miroga-
balin in patients who experienced moderate adverse
events with pregabalin treatment have been published.
In the present study, we examined the outcomes with
mirogabalin as a rescue drug in patients with peripheral
neuropathic pain who developed moderate side effects
from pregabalin treatment.
Methods
Participants
This retrospective study included outpatients with per-
ipheral neuropathic pain who consulted our hospital be-
tween April 2019 and October 2019. Data were collected
from medical records. The diagnosis of peripheral
neuropathic pain was based on a history of neuropathic
pain and confirmatory findings on examination. The in-
clusion criteria were a diagnosis of peripheral neuro-
pathic pain based on the flow chart of the grading
system for neuropathic pain [18], lack of efficacy with
pregabalin (Lyrica®, Pfizer Inc., Tokyo, Japan) or adverse
events with pregabalin treatment, and the willingness to
answer a questionnaire. The exclusion criteria included
dementia, delirium, or other conditions that made it dif-
ficult to complete a self-reported written questionnaire.
Patients with severe chronic diseases that interfered with
treatment (e.g., cardiovascular disease, renal failure, or
other disqualifying conditions) were also excluded. At
baseline, the patients completed a self-reported ques-
tionnaire and provided demographic and clinical infor-
mation. This study was approved by the Kurashiki
Municipal Hospital ethics committee, and written in-
formed consent was waived because of the retrospective
design.
Procedure
Treatment protocol
At least 1 month after cessation from pregabalin, treat-
ment with mirogabalin (Tarlige®, Daiichi Sankyo, Inc.,
Tokyo, Japan) was prescribed. The patients received mir-
ogabalin 10 mg/day orally for the first week. In patients
with decreased renal function, the dose of mirogabalin
was decreased to 5 mg/day. Depending on patient age
and symptoms, the dose of mirogabalin was decreased
or increased as required to between 2.5 mg and 15mg/
dose twice daily. All patients visited the hospital at 1, 2,
4, and 8 weeks to ensure compliance with the study regi-
men. The patients with an adequate effect received the
same dose of mirogabalin. In patients with an inadequate
effect, the dose of mirogabalin was increased up to 30
mg/day. If adverse events were observed, the dose was
decreased. In this study, no other conservative treat-
ments (nonsteroidal anti-inflammatory drugs and
rehabilitation) or surgeries were performed. During the
study, only the dispensing pharmacist had knowledge of
the patient codes. The manufacturer and provider of
mirogabalin (Daiichi Sankyo, Inc., Tokyo, Japan) was not
involved in the protocol development, data collection
and management, statistical analysis, or manuscript
preparation.
Clinical assessment
The neuropathic pain screening questionnaire (NeP
score), developed by Ogawa et al., was used for the per-
ipheral neuropathic pain survey (Table 1) [19–21]. The
patients’ answers to questions in seven domains were
weighted and scored. The likelihood of neuropathic pain
was determined based on the total score as follows: ≥
5 = highly likely to have neuropathic pain; 4 = likely to
have neuropathic pain; 3 = possibility of neuropathic
pain; ≤ 2 = unlikely to have neuropathic pain. A score ≥ 4
was judged as representing neuropathic pain [20]. The
numeric rating scale (NRS) for pain self-assessment is a
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widely used, valid, and reliable tool to measure chronic
pain intensity [22]. The scores ranged from 0 to 10, with
0 representing no pain and 10 representing the worst
pain imaginable. The NRS scores were obtained at base-
line and at 1, 2, 4, and 8 weeks of treatment. We also
evaluated adverse events of mirogabalin.
Primary endpoint
The primary endpoint of this study was to analyze the
treatment course of peripheral neuropathic pain using
NRS scores in patients receiving mirogabalin.
Secondary endpoint
The secondary endpoint of the current study was to in-
vestigate the adverse events of mirogabalin.
Statistical analysis
Factors associated with the cessation of mirogabalin
treatment due to adverse events were identified using
univariate analyses between the patients who continued
treatment and those who ceased from treatment. Differ-
ences in the treatment course (i.e., NRS scores) were
compared using one-way analysis of variance with Bon-
ferroni post hoc tests. Moderate improvements in pain
are considered to be 30%h Bonferroni postnivariate 50%
pain relief is considered a good outcome [23, 24]. There-
fore, we divided patients into two groups based on pain
relief levels of < 30% or ≥ 30% after 8 weeks of treatment
with mirogabalin. Normally distributed variables were
compared using Student’s t-tests, and non-normally dis-
tributed variables were compared using Mann–Whitney
U tests. ables were compared using d using Studentpain
relief levels of <analyses between ain using NRS scores
in pabetween groups. Differences in the magnitude of
NRS improvement between the groups with initial doses
of 5 mg/day and 10mg/day were compared using Stu-
dent’s t-tests. Differences in the magnitude of NRS im-
provement in patients taking maximum doses were
compared using one-way analysis of variance. Differ-
ences of p < 0.05 were considered significant. Statistical
analyses were conducted using SPSS software version
25.0 for Windows (IBM Corporation, Armonk, NY,
USA).
Results
Participants
Of the 337 outpatients with peripheral neuropathic pain
who had been treated with pregabalin, 187 (55.5%) met
the inclusion criteria and were included in this study
(Table 2). Adverse events leading to the switch from preg-
abalin to mirogabalin included somnolence (97 patients,
28.8%), dizziness (50 patients, 14.8%), edema (7 patients,
2.1%), weight gain (3 patients, 0.9%), epigastralgia (2 pa-
tients, 0.6%), and fatigue (2 patients, 0.6%). Thirty-two pa-
tients switched to mirogabalin due to a lack of efficacy
with pregabalin. This study included 58 men and 129
women with a mean age of 72.3 years (range, 30–94 years)
at the time of the baseline examination. The mean pain
duration from onset until consultation was 37months
(range, 3–252months). In this study, 134 patients had
lumbar canal stenosis, 33 had cervical spondylotic myelop-
athy, 10 had lumbar disc herniation, 9 had carpal tunnel
syndrome, and 1 had postoperative pain.
Treatment with mirogabalin
Fifty-nine patients received mirogabalin 10 mg/day orally
for the first week, and 128 patients received mirogabalin
5 mg/day due to decreased renal function. Thirty-three
patients were treated with 5 mg/day for 8 weeks of treat-
ment. Eighty-one patients increased the dose of miroga-
balin to 10 mg/day due to lack of efficacy. Thirty
patients increased the dose of mirogabalin to 20mg/day.
Nineteen patients increased the dose of mirogabalin to
30mg/day; none of these patients experienced severe ad-
verse events with the increased dose. Twenty-four pa-
tients (12.8%) withdrew from mirogabalin treatment
Table 1 Neuropathic pain screening questionnaire
Question
Q1 There is a pinprick-like pain
Q2 There is an electric shock-like pain
Q3 There is a tingling burning pain
Q4 There is pain with strong numbness
Q5 A light touch with clothing or cold wind causes pain
Q6 The site of pain has decreased or increased sensation
Q7 The site of pain shows skin swelling and/or discoloration to red or
purple
Each of the items is scored on a 5-point scale (0 = never; 1 = slight; 2 =
moderate; 3 = strong; 4 = very strong). The total score can range from 0 to 28
points, with higher scores indicating greater pain.
Table 2 Patient characteristics
Variables n = 187
Age (years) 72.3 ± 12.4 (30–94)
Sex, female/male 129/58
Diagnosis
LCS 134
CSM 33
LDH 10
CTS 9
Others 1
BMI (kg/m2) 23.1 ± 4.2 (18–33)
DM 17
Data are expressed as the mean ± standard deviation (range) or n (%)
LCS lumbar canal stenosis, CSM cervical spondylotic myelopathy, LDH lumbar
disc herniation, CTS carpal tunnel syndrome, BMI body mass index, DM
diabetes mellitus
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because of adverse events. Adverse events associated
with mirogabalin included somnolence (50 patients,
26.7%), dizziness (23 patients, 12.3%), edema (11 pa-
tients, 5.9%), epigastric pain (2 patients, 1.1%), weight
gain (1 patient, 0.5%), and fatigue (1 patient, 0.5%). We
investigated factors associated with the cessation of mir-
ogabalin treatment due to adverse events. There were no
significant differences in age, sex, body mass index
(BMI), or diagnosis between the patients who discontin-
ued mirogabalin and those who continued its use (Table
3). The patients who discontinued mirogabalin had a sig-
nificantly lower incidence of somnolence (p = 0.0017)
and significantly higher incidences of dizziness (p =
0.015) and edema (p = 0.012) with pregabalin than those
who continued mirogabalin. The patients who discontin-
ued mirogabalin also had significantly higher incidences
of dizziness (p = 0.0069) and edema (p = 0.016) than the
patients who continued mirogabalin, and these effects
contributed to the cessation of treatment.
We also investigated changes in NRS scores over the
course of treatment with mirogabalin for 8 weeks. After
treatment with mirogabalin for 1 week, NRS scores sig-
nificantly decreased compared with baseline (p < 0.0001,
Fig. 1) and subsequently continued to decrease over
time. After 8 weeks, NRS scores had improved by ≥ 30%
compared with baseline in 113 patients (69.3%). We di-
vided the patients into two groups to identify factors as-
sociated with improvements in NRS scores of < 30% and
≥ 30% after 8 weeks (Table 4). There were no significant
differences in age, sex, diagnosis, or BMI between
groups, but the NeP score was significantly higher in pa-
tients who experienced pain relief < 30% than in those
Table 3 Univariate analyses comparing factors associated with continuation or withdrawal of treatment with mirogabalin
Variables Continued treatment
(n = 163)
Withdrew from treatment
(n = 24)
p value
Age (years) 71.8 ± 12.7 (30–94) 75.0 ± 9.9 (49–91) 0.23a
Sex, female/male 110/53 19/5 0.25b
Diagnosis 0.98b
LCS 118 17
CSM 28 5
LDH 9 1
CTS 8 1
Others 1 0
BMI (kg/m2) 22.9 ± 4.1 (18–33) 23.2 ± 3.9 (19–31) 0.78a
DM 15 2 0.89b
Adverse events with pregabalin
Somnolence 92 (56.4%) 5 (20.8%) 0.0017b
Dizziness 39 (23.9%) 11 (45.8%) 0.015b
Edema 4 (2.5%) 3 (12.5%) 0.012b
Weight gain 3 (1.8%) 0 (0%) 0.51b
Others 2 (1.2%) 2 (8.3%)
Lack of efficacy with pregabalin 27 (16.6%) 5 (20.8%) 0.61b
NeP score (points) 7.0 ± 1.7 (6–12) 6.9 ± 1.7 (6–12) 0.80b
Primary dose of mirogabalin (mg) 3.1 ± 1.2 (5–10) 3.3 ± 1.8 (5–10) 0.52b
Adverse events with mirogabalin
Somnolence 44 (27%) 6 (25%) 0.84b
Dizziness 16 (9.8%) 7 (29.2%) 0.0069b
Edema 7 (4.3%) 4 (16.7%) 0.016b
Epigastric pain 0 (0%) 2 (8.3%) < 0.0001b
Weight gain 1 (0.6%) 0 (0%) 0.70b
Fatigue 1 (0.6%) 0 (0%) 0.70b
Data are expressed as the mean ± standard deviation (range) or n (%).
LCS lumbar canal stenosis, CSM cervical spondylotic myelopathy, LDH lumbar disc herniation, CTS carpal tunnel syndrome, BMI body mass index, DM diabetes
mellitus, NeP neuropathic pain
a Student’s t-test
b Chi-squared test
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who experienced greater levels of pain relief (p = 0.0047).
We examined whether there were differences in the ad-
verse events and magnitude of NRS improvement be-
tween the patients with initial doses of 5 mg/day (n =
128) and 10mg/day (n = 59). The incidence of adverse
events in patients with an initial dose of 5 mg/day (50%,
64/128 patients) was not significantly different from that
in patients with 10mg/day (45.8%, 27/59 patients; p =
0.59). There were no significant differences in the mag-
nitude of NRS improvement between the groups with
initial doses of 5 mg/day (46.5% ± 24.8%) and 10mg/day
(45.5% ± 24.4%; p = 0.81). Similarly, there were no signifi-
cant differences in the magnitude of NRS improvement
in patients taking maximum doses of 5 mg/day (n = 47),
10 mg/day (n = 89), 20 mg/day (n = 32), and 30mg/day
(n = 19, p = 0.79; Fig. 2).
Discussion
In this study, we used mirogabalin to treat patients with
peripheral neuropathic pain who switched from pregaba-
lin treatment to mirogabalin treatment due to lack of ef-
ficacy or adverse events. Mirogabalin is a new drug for
the treatment of peripheral neuropathic pain, and to our
knowledge, there have been no reports of its clinical out-
comes for patients who were previously treated with
pregabalin. Mirogabalin exerted a significant analgesic
effect within 1 week and was associated with mild CNS
adverse effects.
Guidelines for the pharmacologic management of
neuropathic pain recommend drugs acting at α2δ subunits
of voltage-gated calcium channels, serotonin–norepineph-
rine reuptake inhibitors, and tricyclic antidepressants as
first-line agents, neurotropin and tramadol as second-line
agents, and opioids as third-line agents [25]. Several other
Fig. 1 Scores on the numeric rating scale (NRS) were significantly
reduced after 8 weeks of treatment with mirogabalin. Data are
expressed as the mean ± standard deviation. *p < 0.05
Table 4. Univariate analyses of patients with or without 30%
pain relief by mirogabalin
Variables < 30% pain relief
(n = 50)
≥ 30% pain relief
(n = 113)
p value
Age (years) 72.9 ± 11.9 (45–88) 71.3 ± 13.0 (30–94) 0.46a
Sex, female/male 30/20 82/31 0.11b
Diagnosis 0.75b
LCS 35 83
CSM 11 17
LDH 2 7
CTS 2 6
Others 0 1
BMI (kg/m2) 22.7 ± 4.2 (18–33) 23.0 ± 3.8 (19–31) 0.79a
DM 4 11 0.72b
NeP score (points) 7.4 ± 2.1 (6–12) 6.6 ± 1.4 (6–12) 0.0047a
Primary doze (mg) 3.1 ± 1.5 (5–10) 3.1 ± 1.1 (5–10) 0.97a
Max dose (mg) 6.6 ± 3.8 (5–30) 6.4 ± 3.8 (5–30) 0.76a
Adverse events 24 (48%) 42 (37.2%) 0.13b
Somnolence 17 (34%) 27 (23.9%)
Dizziness 6 (12%) 10 (8.8%)
Edema 2 (4%) 5 (4.4%)
Weight gain 1 (2%) 0 (0%)
Data are expressed as the mean ± standard deviation (range) or n (%).
LCS lumbar canal stenosis, CSM cervical spondylotic myelopathy, LDH lumbar
disc herniation, CTS carpal tunnel syndrome, BMI body mass index, DM
diabetes mellitus, NeP neuropathic pain
a Student’s t-test
b Chi-squared test
Fig. 2 The magnitude of numeric rating scale (NRS) improvement
after 8 weeks of treatment with mirogabalin. No significant differences
were observed in the magnitude of NRS improvement in patients
taking maximum doses of 5mg/day (n = 47), 10mg/day (n = 89), 20
mg/day (n = 32), and 30mg/day (n = 19). Data are expressed as the
mean ± standard deviation. N.S., not significant
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scientific associations and guidelines recommend gaba-
pentinoids as first-line drugs for the treatment of neuro-
pathic pain [26–29]. Mirogabalin, a ligand for the α2δ
subunits (α2δ-1 and α2δ-2) of voltage-sensitive calcium
channels in the CNS, was approved as a medication for
pain relief in patients with peripheral neuropathic pain in
2019 in Japan. Mirogabalin reportedly relieved diabetic
peripheral neuropathic pain in a dose-dependent manner
in Asian patients with diabetic peripheral neuropathic
pain and was associated with only mild adverse events
[30]. It was also shown to be effective and well tolerated in
the management of postherpetic neuralgia in Asian pa-
tients [31]. In the present study, which included only pa-
tients who withdrew from pregabalin treatment due to
adverse events or lack of efficacy, we found that mirogaba-
lin was an effective analgesic and that few patients stopped
treatment due to adverse events.
In vitro studies of its pharmacologic action have demon-
strated that mirogabalin had a higher binding affinity for
the human and rat α2δ subunit than pregabalin [16]. In a
dissociation rate analysis, the dissociation half-lives of mir-
ogabalin from the α2δ-1 and α2δ-2 subunits were 11.1 h
and 2.4 h, respectively, compared with 1.4 h for pregabalin
at both subunits [16]. These reports indicated that miro-
gabalin has potent and selective binding affinities for the
human and rat α2δ subunit and a slower dissociation rate
for the α2δ-1 subunit than the α2δ-2 subunit compared
with pregabalin [16]. These findings support our results
that even patients who discontinued pregabalin because of
its CNS effects experienced fewer adverse events when
they were treated with mirogabalin. In this study, the ini-
tial dose was reduced to 5mg/day in patients with im-
paired renal function or in the elderly patients. In patients
with impaired renal function, we consider that the initial
dose of 10mg/day was too high, which may cause adverse
events. However, in this study, the incidence of adverse
events was nearly the same in the patients with impaired
renal function as in the patients with normal renal func-
tion, and there was no significant difference in the magni-
tude of NRS improvement after 8 weeks of treatment.
Therefore, we consider that administering a reduced dose
is useful in patients with impaired renal function. It has
also been reported that continued oral mirogabalin treat-
ment increases the pain threshold over time [16]. In ani-
mal models of fibromyalgia, mirogabalin treatment has
been shown to significantly decrease pain scores due to
chronic allodynia [32]. Neuropathic pain results in higher
pain scores than nociceptive pain [4]. In this study, the
dose of mirogabalin was increased in response to pain
over an 8-week treatment period. The magnitude of NRS
improvement was 40% or more at the 10mg/day, 20 mg/
day, and 30 mg/day doses, and the analgesic effect of mir-
ogabalin was evident after only 1 week, suggesting a good
analgesic effect of mirogabalin.
The α2δ-1 subunit plays an important role in the on-
set and pathological persistence of neuropathic pain.
Α2δ-1 expression levels correlated with tactile allodynia
development were significantly increased in rats with
spinal cord injury [33]. Knockdown of the α2δ-1 subunit
by antisense oligodeoxynucleotides reportedly inhibited
tactile allodynia in rat models [33, 34]. Overexpression
of the α2δ-1 subunit resulted in enhanced currents, al-
tered kinetics, and voltage-dependence of voltage-gated
calcium channel activation in sensory neurons; exagger-
ated and prolonged dorsal horn neuronal responses to
mechanical and thermal stimulations in the periphery;
and enhanced pain-related behavior [35]. To the best of
our knowledge, no study has addressed the association
between the α2δ-2 subunit and pain. Edvardson et al. re-
ported the importance of the α2δ-2 subunit, which is
dominantly expressed in cerebellar Purkinje cells, in the
normal physiology of the human brain [36]. Binding to
the α2δ-1 subunit contributes to analgesic effects,
whereas binding to the α2δ-2 subunit appears to con-
tribute to undesirable CNS effects, such as somnolence
[37–39]. These studies indicated that gabapentinoids
exert their analgesic effects via the α2δ-1 subunit, and
the α2δ-1 subunit thus plays a major role in neuropathic
pain. These findings suggested that the α2δ-2 subunit
may be implicated in the CNS adverse events commonly
seen with pregabalin treatment. These findings also sug-
gested that the selective actions of mirogabalin on the
α2δ-1 and α2δ-2 subunits may maximize its analgesic ef-
fects while minimizing CNS adverse events. The potent
binding affinity of mirogabalin with the α2δ-1 subunit
and its long dissociation half-life from the α2δ-2 subunit
may thus make mirogabalin an attractive agent for the
treatment of peripheral neuropathic pain. Although
12.8% of patients in the present study discontinued
treatment because of adverse events, mirogabalin was
generally well tolerated.
Although the results of the present study suggest that
mirogabalin might be an alternative treatment option for
the treatment of peripheral neuropathic pain, the present
study has some limitations. First, both pregabalin and
mirogabalin are ligands for the α2δ subunit of voltage-
sensitive calcium channels. However, this study had no
pretrial protocol and is a case series without a compari-
son or placebo group. We did not compare these two
drugs in this study. Thus, the results cannot be clearly
attributed to mirogabalin administration. Second, this
study had a short observation period. Although most pa-
tients treated with mirogabalin for 8 weeks maintained
their weight within ± 5% of their baseline weight, weight
gain can be an issue with mirogabalin when used for a
longer period. A third limitation was a lack of determin-
ation of the best screening questionnaire for neuropathic
pain. Neuropathic pain screening questionnaires include
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painDETECT [4], the spine painDETECT questionnaire,
which is a screening tool for neuropathic pain caused by
spinal disorders [40], and the NeP score used in this
study. We considered that if the NeP scores were high,
there would be little decrease in NRS scores after miro-
gabalin treatment, making it suitable as a baseline index.
However, the use of other neuropathic pain screening
questionnaires might have led to different results. We
consider that the assessment and diagnosis of neuro-
pathic pain should follow an identical algorithm that is
widely used as a current international standard for the
diagnosis of neuropathic pain, and it should specifically
include (1) an assessment of the range of pain that is
neuroanatomically plausible, (2) the suggestion of a le-
sion or disease of the somatosensory system, and (3) ob-
jective findings of sensory damage that are observed in
the neuroanatomically innervated region of the damaged
nerve or tests that are performed to provide a diagnosis
of a neurological lesion or disease that accounts for the
neuropathic pain. Despite these limitations, mirogabalin,
a recently developed agent, showed promising results in
patients with peripheral neuropathic pain.
Conclusions
This investigation indicated that mirogabalin is safe and
effective for reducing peripheral neuropathic pain in pa-
tients who ceased treatment with pregabalin due to ad-
verse events or lack of efficacy.
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